Caffeine consumption and risk of dyskinesia in CALM-PD

Caffeine for treatment of Parkinson disease: A randomized controlled trial

(2012) R. B. Postuma et al.   NEUROLOGY

Therapies for dopaminergic-induced dyskinesias in parkinson disease

(2011) Mildred D. Gottwald et al.   ANNALS OF NEUROLOGY

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

(2011) Robert A Hauser et al.   LANCET NEUROLOGY

Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study

(2011) Robert D. Altman et al.   MOVEMENT DISORDERS

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

(2011) A. F. Ramlackhansingh et al.   NEUROLOGY

Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients

(2011) Masahiro Mishina et al.   PLoS One

Genome-Wide Gene-Environment Study Identifies Glutamate Receptor Gene GRIN2A as a Parkinson's Disease Modifier Gene via Interaction with Coffee

(2011) Taye H. Hamza et al.   PLoS Genetics

Deletion of adenosine A1 or A2A receptors reduces l-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease

(2010) Danqing Xiao et al.   BRAIN RESEARCH

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study

(2010) Yoshikuni Mizuno et al.   MOVEMENT DISORDERS

Caffeine and Progression of Parkinson Disease

(2009) David K. Simon et al.   CLINICAL NEUROPHARMACOLOGY

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

(2008) Robert A. Hauser et al.   MOVEMENT DISORDERS